Cargando…

Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation or Treated with Immunomodulatory Agents.

Multiple myeloma (MM) is associated with a significant risk of infection due to immune dysfunction. Infections are a major cause of morbidity and mortality in MM patients. There are few data available regarding the prevalence of infection in MM patients, especially in conjunction with newer generati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khalafallah, Alhossain, Maiwald, Matthias, Cox, Amanda, Burns, Denise, Bates, Gerald, Hannan, Terry, Seaton, David, Fernandopulle, Bernadene, Meagher, Damien, Brain, Terry
Formato:	Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033112/ https://www.ncbi.nlm.nih.gov/pubmed/21415947 http://dx.doi.org/10.4084/MJHID.2010.005

Ejemplares similares

Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia
por: Khalafallah, Alhossain, et al.
Publicado: (2010)

An Unusual Presentation of Desmoplastic Small Round Cell Tumour of the Abdomen: Morphological, Immunohistochemical, Ultrastructural, and Molecular Studies
por: Angunawela, Preethika, et al.
Publicado: (2011)

Successful Treatment with Thrombopoietin Receptor Agonist in Avoiding Splenectomy for Patients with Chronic Refractory Immune Thrombocytopenia
por: Khalafallah, Alhossain, et al.
Publicado: (2012)

Glycosylated haemoglobin for screening and diagnosis of gestational diabetes mellitus
por: Khalafallah, Alhossain, et al.
Publicado: (2016)

Concurrent Hairy Cell Leukemia and Metastatic Merkel Cell Carcinoma
por: Prakash, Ajay, et al.
Publicado: (2018)

Iron Deficiency Anaemia in Pregnancy and Postpartum: Pathophysiology and Effect of Oral versus Intravenous Iron Therapy
por: Khalafallah, Alhossain A., et al.
Publicado: (2012)

Quality of Life Assessment in Multiple Myeloma Patients Undergoing Dose-Reduced Tandem Autologous Stem Cell Transplantation
por: Khalafallah, A., et al.
Publicado: (2011)

Alternative Immunomodulatory and Disease-Modifying Treatment for Atopic Dermatitis: Autologous Total Immunoglobulin G
por: Kim, Su Min, et al.
Publicado: (2020)

Review of Management and Outcomes in Women with Thrombophilia Risk during Pregnancy at a Single Institution
por: Khalafallah, Alhossain A., et al.
Publicado: (2014)

Venous thromboembolism in medical patients during hospitalisation and 3 months after hospitalisation: a prospective observational study
por: Khalafallah, Alhossain A, et al.
Publicado: (2016)

Early Application of High Cut-Off Haemodialysis for de-Novo Myeloma Nephropathy is Associated with Long-Term Dialysis-Independency and Renal Recovery
por: Khalafallah, Alhossain A., et al.
Publicado: (2013)

Assessment of whole body MRI and sestamibi technetium-99m bone marrow scan in prediction of multiple myeloma disease progression and outcome: a prospective comparative study
por: Khalafallah, Alhossain A, et al.
Publicado: (2013)

Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma
por: Batra, Anu, et al.
Publicado: (2014)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

High Serum Erythropoietin and Ferritin Levels in Conjunction with Anemia Response in Malignant Lymphoma
por: Omari, Sofia, et al.
Publicado: (2011)

Efficacy, Safety, and Immunomodulatory Effect of the Intramuscular Administration of Autologous Total Immunoglobulin G for Atopic Dermatitis: A Randomized Clinical Trial
por: Nahm, Dong-Ho, et al.
Publicado: (2020)

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma
por: Hus, Marek, et al.
Publicado: (2011)

Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma
por: Di Lullo, Giulia, et al.
Publicado: (2019)

Extramedullary Plasmacytoma of the Tonsil with Nodal Involvement
por: Bazaadut, Simon, et al.
Publicado: (2010)

Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
por: Patel, Urmeel H., et al.
Publicado: (2015)

Adherence to immunomodulatory drugs in patients with multiple myeloma
por: Cransac, Amélie, et al.
Publicado: (2019)

Intramuscular administration of autologous total immunoglobulin G induces immunomodulatory effects on T cells in healthy human subjects: An open-labeled prospective single-arm trial
por: Kwon, Byul, et al.
Publicado: (2022)

Maintenance Therapy with Immunomodulatory Drugs after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
por: Ye, Xueshi, et al.
Publicado: (2013)

Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma
por: Ozaki, Shuji, et al.
Publicado: (2019)

Immunomodulatory activity accompanying chicken egg yolk immunoglobulin Y
por: Polanowski, A., et al.
Publicado: (2012)

Immunoglobulin Glycosylation – An Unexploited Potential for Immunomodulatory Strategies in Farm Animals
por: Zlatina, Kristina, et al.
Publicado: (2021)

Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation
por: Mimura, Yusuke, et al.
Publicado: (2022)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Erratum: Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation
Publicado: (2022)

Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia
por: Colado, Ana, et al.
Publicado: (2021)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
por: Thakurta, Anjan, et al.
Publicado: (2021)

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma
por: Chen, Lucia Y., et al.
Publicado: (2022)

Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs
por: Takamatsu, Hiroyuki, et al.
Publicado: (2023)

Efficacy of Immunomodulatory Drugs in Combination With Dexamethasone in Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits
por: Zhou, Houan, et al.
Publicado: (2022)

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma
por: González-Calle, Verónica, et al.
Publicado: (2017)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
por: Swan, Dawn, et al.
Publicado: (2020)

Autologous transplant for myeloma: when the old meets the new
por: Gay, Francesca, et al.
Publicado: (2017)

Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
por: Minnie, Simone A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t2jul2s6t5htcltnm6hh3nrj90